Background. While the necessity of treatment of hepatitis C virus (HCV)-infected patients with advanced liver disease is widely accepted, the benefit of treating patients without significant liver disease is less well established. Our aim was to assess the effect of treating HCV in patients with no or minimal fibrosis (Metavir stage F0-F1) on patient-reported outcomes (PROs).
Over the last decade, there has been increasing recognition that hepatitis C virus (HCV) infection is, in fact, a systemic infection associated with negative clinical, economic, and also patient-reported outcomes (PROs) including impaired health-related quality of life (HRQL) [1] [2] [3] [4] [5] [6] . Patients with HCV infection commonly experience fatigue, depression, anxiety, cognitive impairment, painful muscle and joint symptoms, irritability, nausea, abdominal discomfort, and right upper quadrant pain [7] [8] [9] [10] . Although some of these are considered "symptoms" of HCV infection, others are established extrahepatic manifestations of HCV, and both negatively impact patients' HRQL and other PROs [2, 6] . In this context, their underlying biological mechanisms and how they impact different organs (brain, muscle, etc) remain largely uncertain, although some studies have suggested a direct link to excessive release of inflammatory cytokines, altered lipid and glucose metabolism, and the direct presence of HCV in the central nervous system, which would alter neurotransmission and brain metabolism [11] [12] [13] [14] [15] [16] [17] [18] . In fact, these symptoms tend to be present irrespective of the stage of hepatic fibrosis [7, 8] . Although these symptoms may not be life-threatening, they cause substantial impairment in patients' HRQL, work productivity, and everyday functionality.
In parallel to the increasing recognition of HCV infection as a systemic disease with both hepatic and extrahepatic manifestations, there has also been tremendous progress in developing effective and well-tolerated treatment regimens to cure HCV infection. Although the previous generation of antiantiviral (DAA) regimens has led to an almost universal cure with excellent safety profiles [19] . Despite this, although IFNbased treatment regimens have been abandoned in the West, a number of countries with high prevalence of HCV continue to offer these regimens [20] [21] [22] . However, to achieve the goals set by the World Health Organization to identify and treat 90% and 80% of HCV infections worldwide by 2030, access to a simple regimen free of IFN will become critical [23] . In this context, it is also important to note that in addition to improvement of clinical outcomes, IFN-free regimens have been associated with on-treatment and post-sustained virologic response (SVR) improvement of PROs in different HCV patient populations [3, 4, 24, 25] .
In the context of advances in HCV treatment, a major challenge is to provide access to treatment to all HCV-infected patients, which is still a work in progress even in Western countries where these regimens have been shown to be cost-effective [2, 4, [26] [27] [28] . In fact, there has been significant debate about the budgetary impact of these new treatment regimens, and barriers to treatment have been created by payers to prevent patients with early fibrosis to be treated with these highly effective treatment regimens. Some payers in the United States, including some states' Medicaid programs, have refused to cover the costs of treatment with DAAs for HCV-infected patients without advanced liver disease [29] , despite evidence that substantial long-term savings can be achieved by treating HCV-infected patients earlier rather than in later stages of their liver disease [30, 31] .
Prior studies suggested notable improvement of PROs in cured HCV patients with bridging fibrosis and cirrhosis following treatment with DAAs [32] [33] [34] . However, no similar data are available for patients without advanced liver disease and, in particular, for those with minimal or no fibrosis. Therefore, the aim of this study was to assess the potential PRO benefits of treating that patient population.
METHODS
We used PRO data collected as exploratory endpoints in 16 phase 3 clinical trials of anti-HCV treatment regimens with sofosbuvir (SOF) [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . The trials were conducted in 2012-2017 in the United States, Canada, Europe, Australia, and New Zealand. Patients were treated with pegylated IFN + ribavirin (RBV) + SOF, or with SOF + RBV, or with fixed-dose combinations of SOF and ledipasvir (LDV) or SOF and velpatasvir (VEL) or SOF/VEL and voxilaprevir (VOX), or with LDV/SOF + RBV for 8-24 weeks. Treatment regimens were assigned based on patients' genotype, cirrhosis status, and treatment history, with or without stratified randomization, and were blinded or not to the study participants. Enrolled patients were treatment-naive or -experienced, of all HCV genotypes, with or without cirrhosis or coinfection with human immunodeficiency virus (HIV), without coinfection with hepatitis B virus or any other major comorbidity based on the screening assessment by the studies' investigators.
Assessment of Patient-Reported Outcomes
Patient-reported outcomes were prospectively collected using 4 different well-validated instruments: 36-Item Short-Form Survey version 2 (SF-36), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV), and Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP) [46] [47] [48] [49] [50] [51] . All instruments were self-administered prior to initiation of any study-related activities at baseline visit (the first day of treatment), and then at prespecified visits during treatment and in posttreatment follow-up. Both site staff and patients were blinded to patients' most recent HCV RNA levels and other laboratory data. Combined together, the 4 instruments return 26 different PRO scores. For presentation purposes, where stated explicitly, PROs were transformed from their original scales to a universal 0-100 scale.
Assessment of Hepatic Fibrosis
During pretreatment screening, Fibrotest [52] and aspartate aminotransferase-to-platelet ratio (APRI) [53] scores were calculated for all participants. No or minimal fibrosis (Metavir stage F0-F1) was presumed in patients with Fibrotest score of ≤0.31 and APRI score of ≤0.7 and no histologic evidence of cirrhosis on a biopsy or transient elastography if available. This definition of F0-F1 was evaluated for accuracy in a subsample of patients with recent (<2 years) liver biopsies.
Statistical Analysis
Patients with F0-F1 by Fibrotest were included in this post hoc analysis. For validation purposes, the same PRO analysis was also run in a subgroup of subjects with a liver biopsy (histologically documented F0-F1) or transient elastography (<5 kPa) available. Patients treated with different regimens were grouped as follows: patients treated with an IFN + RBV-containing regimen (IFN + RBV + SOF), with IFN-free RBV-containing regimens (SOF + RBV or LDV/SOF + RBV), and with IFNfree RBV-free regimens (LDV/SOF or SOF/VEL or SOF/VEL/ VOX), regardless of duration.
Demographic and clinical parameters and PRO scores were summarized by the treatment regimen group and were compared between the 3 groups using Kruskal-Wallis nonparametric test (continuous parameters) or χ 2 test (categorical parameters).
The changes (decrements or improvements) in PRO scores from patients' own baseline levels were calculated and tested for statistical significance using Wilcoxon signed-rank test. P values of ≤.05 were considered statistically significant.
Independent predictors of PRO scores were assessed using generalized mixed regression models with stepwise selection of predictors. The list of potential fixed-effect PRO predictors included age, sex, race, location, treatment history, body mass index, history of clinically overt fatigue and psychiatric disorders, type 2 diabetes, coinfection with HIV, and baseline Fibrotest score; in addition, clustering by the study was tested as a random effect. After treatment initiation, treatment regimen and baseline PRO level were added as potential fixed-effect PRO predictors.
All analyses were run in SAS software version 9.4 (SAS Institute, Cary, North Carolina). The study was separately approved by each site's institutional review board.
RESULTS
Of 6810 patients with HCV and available Fibrotest and APRI data enrolled in the 16 clinical trials, 1548 had no or minimal fibrosis (F0-F1) per our definition, and were included in this study. The cohort was, on average, 46 ± 11 years old, 43% male, 82% white, 61% enrolled in the United States, 5% diabetic, 81% treatment naive, and 10% coinfected with HIV (Table 1) .
Patient-Reported Outcomes in Patients With HCV and No or Minimal Fibrosis
Baseline PRO scores of patients with HCV and F0-F1 are shown in Supplementary Table 2. Compared to the general population norms (SF-36) [46] , those were similar or higher (all 1-sided P > .05). After treatment initiation, however, the trends in PROs followed different directions depending on the regimen used ( Figure 1 ).
During treatment, PROs of patients treated with the IFN + RBV-containing regimen were profoundly impaired: Indeed, the average decrements up to -28.7 points on a 0-100 PRO score were observed at the end of treatment; the greatest impairment was in Role Physical of SF-36 (P < .01 for all but 2 PROs; the exceptions were Worry of CLDQ-HCV and Emotional Abbreviations: ALT, alanine aminotransferase; APRI, aspartate aminotransferase-to-platelet ratio index; BMI, body mass index; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; RBV, ribavirin; SOF, sofosbuvir; ULN, upper limit of normal. Figure 2A ; Supplementary Figure 1A ). Similarly assessed PRO decrements in the IFN-free RBV-containing group were also statistically significant (P < .05 for 17 of 26 PROs by the end of treatment), but the magnitude of those decrements was relatively modest (from -1.9 to -7.3 points by treatment week 4, from -2.2 to -8.9 points on average by the end of treatment; the greatest impairment was in Work Productivity) and was also accompanied by improvements in General Health of SF-36, EWB of FACIT-F, and Worry of CLDQ-HCV by average +1.8 to +8.2 points (P ≤ .01) (Figure 2A ; Supplementary Figure 1A) . In contrast, substantial PRO improvements (average +1.2 to +8.2 points, P < .05 for 18 of 26 PROs, by treatment week 4; +1.2 to +10.9 points, P < .05 for 24 of 26 PROs, by the end of treatment) were observed in the IFN-free RBV-free group; the greatest improvement was in Worry and EWB (Figure 2A; Supplementary Figure 1A) . Within the studied treatment-regimen groups, treatment-emergent changes in PROs in HCV-infected patients with stage F0-F1 were similar between different regimens, such as between SOF + RBV and LDV/SOF + RBV or between LDV/ SOF, SOF/VEL, and SOF/VEL/VOX (all but one P > .05 [P < .05 for SF-6D utility score, which did not improve in SOF/VELtreated group]).
Well-Being [EWB] of FACIT-F) (
After treatment cessation, some residual PRO decrements remained significant by posttreatment week 4 in patients who completed the IFN + RBV-containing regimen (average -4.3 to -10.1 points from the baseline level, P < .05 for 7 of 26 PROs; the greatest residual impairment was in Role Physical) ( Figure 2B ; Supplementary Figure 1B) . In contrast, all observed PRO decrements completely resolved in patients who completed the IFN-free RBV-containing regimens (all one-sided P > .05), and improvements ranging from, on average, +1.2 to +10.1 points were achieved (P < .05 for 13 of 26 PROs; the greatest improvement in Worry and EWB) ( Figure 2B; Supplementary Figure 2B) . At the same time point, in patients who completed the IFN-free RBV-free regimens, the PRO improvements observed at the end of treatment sustained or increased (range, +2.6 to +12.4 points, P < .05 for all PROs except for Absenteeism); the greatest improvement was in Worry and Activity/Energy of CLDQ-HCV ( Figure 2B; Supplementary Figure 2B) .
By SVR at 12 weeks (SVR 12 ), in the IFN + RBV-containing group, all residual PRO decrements resolved (all one-sided P > .05), and improvements from, on average, +4.4 to +14.7 points from the baseline levels (P < .05 for 9 of 26 PROs) were observed; the greatest improvement was in Worry and EWB ( Figure 3A; Supplementary Figure 2A) . On the other hand, PRO improvements observed in both IFN-free treatment groups sustained or increased: from average +1.3 to +10.3 points (P < .05 for 17 of 26 PROs) in the IFN-free RBV-containing group (the greatest in Worry and Emotional of CLDQ-HCV), from average +2.9 to +12.9 points in IFN-free RBV-free group (all but 1 P < .0001; the greatest improvement in Worry and Activity/Energy of CLDQ-HCV) ( Figure 3A ; Supplementary  Figure 2A) .
By SVR 24 , the PRO improvements kept increasing to, on average, +5.6 to +18.2 points (P < .05 for 15 of 26 PROs; the greatest in Worry and Emotional of CLDQ-HCV) in the IFN + RBV-containing group, +2.2 to +12.9 points (P < .05 for 23 of 26 PROs; the greatest in the domains of CLDQ-HCV), +4.5 to +15.2 points (P < .0001 for 25 of 26 PROs; the greatest in the domains of CLDQ-HCV, Vitality, and Activity of WPAI-SHP) in the IFNfree RBV-free group ( Figure 3B; Supplementary Figure 2B) . Furthermore, at that time point, treatment-emergent changes in PROs were no longer different between the regimens (all trend P > .05).
Predictors of Patient-Reported Outcomes in HCV-Infected Patients With Fibrosis Stage F0-F1
Independent predictors of baseline summary PROs in the study cohort are summarized in Table 2 . After treatment initiation, adjusted for clinicodemographic PRO predictors and baseline PRO levels, being treated with IFN + RBV was independently associated with an impairment in summary PROs ranging from -14.9 to -28.5 points (reference regimen: IFN-free, RBV-free). Similarly, calculated impairment associated with the use of IFN-free RBV-containing regimens ranged from -5.3 to -10.6 points ( Figure 4A ). By SVR 12 , impairment associated with the use of IFN was no longer significant except for SF-6D utility score ( Figure 4B ). 
Subgroup Analysis in Subjects With No or Minimal Fibrosis by Histology or Transient Elastography
Among 6810 patients originally included, 2719 had either liver biopsy (n = 1497) or transient elastography (n = 1246) available, and of those, 1002 had F0-F1 (histologic or <5 kPa) including 358 treated with IFN-free RBV-containing regimens, and 644 treated with IFN-free RBV-free regimens. All observations made in this study were reproduced in this subgroup of patients, including moderate and reversible PRO decrements in those treated with RBV (-1.7 to -5.4 points by the end of treatment, P < .05 for 14 of 26 PROs with the greatest in Work Productivity; all one-sided P > .05 by posttreatment week 4) contrasted to early and sustainable PRO improvements in those treated with the IFN-free RBV-free regimens (+1.2 to +8.3 for 14 of 26 PROs by treatment week 4; +1.7 to +11.6 points for 24 of 26 PROs by the end of treatment; the greatest in Worry and EWB; Supplementary Figure 3A) . Post-SVR PRO improvements were also similar between the treatment regimen groups, also consistent with the original analysis (Supplementary Figure 3B) .
Comparison of PRO Changes to Patients With Higher Degrees of Fibrosis
To add context to presented observations, we used the PRO data collected from controls with higher degrees of fibrosis treated in the same clinical trials with the same regimens. The control cohort included 3713 patients with F2-F3 (Fibrotest >0.31 or APRI >0.7 without cirrhosis) and 1534 with F4 (compensated cirrhosis). Although some of the reported PRO gains were more prominent in patients with more advanced liver disease, the majority of treatment-and SVR-related PRO improvements were found to be similarly significant across fibrosis stages (Supplementary Figure 4) .
DISCUSSION
Recently, there has been substantial interest about the impact of HCV infection and various treatment regimens on PROs. Studies have demonstrated that HCV itself is responsible for a decrement in patients' HRQL, and treatment with IFN-based regimens further impairs HRQL [2] [3] [4] . In contrast, treatment with IFN-free RBV-free DAAs can improve PROs as early as 2 weeks into treatment [54] . Most of those studies included patients with significant liver disease, whereas there are no publications focusing on PROs in patients with no or minimal fibrosis.
As such, in the largest analysis of PRO data for HCV-infected patients without significant hepatic fibrosis, we identified the clear PRO superiority of IFN-and RBV-free regimens during treatment. In fact, F0-F1 patients who were treated with an IFNbased regimen experienced substantial PRO declines, which were the most prominent in the domains related to patients' everyday productivity (Role Physical, Work Productivity Impairment). It is important to note that although IFN-based regimens have been largely abandoned, they are still being used in some parts of the world solely because of lower budgetary impact and despite their inferiority in regard to their efficacy, safety, and tolerability accompanied by their substantial negative impact on PROs. At the same time, F0-F1 patients treated with IFN-and RBV-free regimens showed significant improvement of most of their PROs during treatment, confirming that this patient population also receives significant benefit from the use of those regimens. This better patient experience lends more evidence to the suggestion that all patients with HCV should be treated with DAAs regardless of their disease stage; the latter could be additionally supported by the reported PRO improvements in patients with F0-F1 being similar to those observed in patients with higher degrees of fibrosis or cirrhosis.
Also encouraging is that after treatment, HCV-infected patients without significant liver disease achieved very high SVR rates, especially patients treated with IFN-and RBV-free regimens who experienced an SVR 12 rate of almost 98%. It is important to note the sustainability of reported PRO improvements. In fact, patients with SVR 12 experienced substantial improvement in most of their PRO scores, which continued up to 24 weeks in posttreatment follow-up. Although these improvements in PROs were eventually seen with all regimens, they were the most rapid and prominent with the IFN-and RBV-free regimens. In fact, improvements in PRO scores after treatment with those regimens exceeded the minimal clinically important difference [55] of 5% of a PRO range size in 25 of 26 PRO domains assessed in this analysis, including Vitality, Bodily Pain, Activity and Energy, Fatigue, Physical Functioning, and Work Productivity. The only PRO that did not improve during treatment or in follow-up was the Absenteeism component of Work Productivity, suggesting that this particular PRO is strongly influenced by factors other than patients' health, such as socioeconomic or policy-related factors. On the other hand, the most prominent improvements were consistently seen in the domains related to mental health (Worry, EWB, Emotional score of CLDQ-HCV). This might be the result of resolution of HCV-related impact on the brain (such as depression or "brain fog" of HCV) after virologic clearance [15, 56] . Since in this study patients' depression status was not reassessed after treatment cessation, further studies are needed to confirm that hypothesis and to link the changes in PROs to clinical events and, ultimately, to underlying pathophysiologic processes.
Finally, our data confirm previously known predictors of PRO scores in patients with HCV. In particular, we have shown that in patients with early liver disease, psychiatric diseases (depression and anxiety), clinically overt fatigue, and type 2 diabetes are the most consistent independent predictors of PRO impairment. It is important to note that some of these conditions associated with PRO impairments have been well documented as extrahepatic manifestations of HCV infection. Again, as posttreatment status of those comorbidities was not evaluated in this study, further studies are needed to relate their resolution to improvement in PROs after virologic clearance. In summary, this analysis of a large cohort of subjects with HCV with no or minimal liver disease shows clear improvement of patients' experience once HCV infection is cured. Combined with the evidence that achieving SVR is associated with a reduction in cirrhosis and hepatocellular carcinoma, and improvement in extrahepatic manifestations and liver-related mortality [57] , this provides additional support to the idea that all patients with HCV must be treated, while the patient-centered approach must focus not only on the clinical benefits but also on PRO benefits. This should inform clinicians and policy makers to remove barriers for treatment of HCV infection regardless of patients' stage of liver disease for the benefit of patients, families, and society.
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